307 related articles for article (PubMed ID: 19715862)
1. Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center.
Rodríguez-Moreno A; Ridao N; García-Ledesma P; Calvo N; Pérez-Flores I; Marques M; Barrientos A; Sánchez-Fructuoso AI
Transplant Proc; 2009; 41(6):2163-5. PubMed ID: 19715862
[TBL] [Abstract][Full Text] [Related]
2. Resolution of sirolimus-induced pneumonitis after conversion to everolimus.
Rehm B; Keller F; Mayer J; Stracke S
Transplant Proc; 2006 Apr; 38(3):711-3. PubMed ID: 16647451
[TBL] [Abstract][Full Text] [Related]
3. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
[TBL] [Abstract][Full Text] [Related]
4. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
[TBL] [Abstract][Full Text] [Related]
5. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus-induced pneumonitis following liver transplantation.
Roberts RJ; Wells AC; Unitt E; Griffiths M; Tasker AD; Allison ME; Bradley JA; Watson CJ
Liver Transpl; 2007 Jun; 13(6):853-6. PubMed ID: 17539005
[TBL] [Abstract][Full Text] [Related]
7. Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience.
Errasti P; Izquierdo D; Martín P; Errasti M; Slon F; Romero A; Lavilla FJ
Transplant Proc; 2010 Oct; 42(8):3053-4. PubMed ID: 20970608
[TBL] [Abstract][Full Text] [Related]
8. Four cases of sirolimus-associated interstitial pneumonitis: identification of risk factors.
Morath C; Schwenger V; Ksoll-Rudek D; Sommerer C; Beimler J; Schmidt J; Zeier M
Transplant Proc; 2007; 39(1):99-102. PubMed ID: 17275483
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus-induced pneumonitis after renal transplantation: a single-center experience.
Lee HS; Huh KH; Kim YS; Kim MS; Kim HJ; Kim SI; Joo DJ
Transplant Proc; 2012 Jan; 44(1):161-3. PubMed ID: 22310604
[TBL] [Abstract][Full Text] [Related]
10. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
[TBL] [Abstract][Full Text] [Related]
11. Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome--a single-centre experience and review of the literature.
Weiner SM; Sellin L; Vonend O; Schenker P; Buchner NJ; Flecken M; Viebahn R; Rump LC
Nephrol Dial Transplant; 2007 Dec; 22(12):3631-7. PubMed ID: 17611248
[TBL] [Abstract][Full Text] [Related]
12. Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: experience of a single center.
Fernandez-Valls M; Gonzalez-Vilchez F; de Prada JA; Ruano J; Ruisanchez C; Martin-Duran R
Transplant Proc; 2005 Nov; 37(9):4021-3. PubMed ID: 16386615
[TBL] [Abstract][Full Text] [Related]
13. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up.
Rothenburger M; Teerling E; Bruch C; Lehmkuhl H; Suwelack B; Bara C; Wichter T; Hinder F; Schmid C; Stypmann J
J Heart Lung Transplant; 2007 Mar; 26(3):250-7. PubMed ID: 17346627
[TBL] [Abstract][Full Text] [Related]
14. Conversion to everolimus in kidney transplant recipients: a safe and simple procedure.
Ruiz JC; Sanchez-Fructuoso A; Rodrigo E; Conesa J; Cotorruelo JG; Gómez-Alamillo C; Calvo N; Barrientos A; Arias M
Transplant Proc; 2006 Oct; 38(8):2424-6. PubMed ID: 17097956
[TBL] [Abstract][Full Text] [Related]
15. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients.
Tenderich G; Fuchs U; Zittermann A; Muckelbauer R; Berthold HK; Koerfer R
Clin Transplant; 2007; 21(4):536-43. PubMed ID: 17645716
[TBL] [Abstract][Full Text] [Related]
16. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
Pediatr Transplant; 2006 Jun; 10(4):474-8. PubMed ID: 16712606
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
[TBL] [Abstract][Full Text] [Related]
18. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
[TBL] [Abstract][Full Text] [Related]
19. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients.
Boratyńska M; Banasik M; Watorek E; Falkiewicz K; Patrzałek D; Szyber P; Klinger M
Transplant Proc; 2006; 38(1):101-4. PubMed ID: 16504675
[TBL] [Abstract][Full Text] [Related]
20. mTOR inhibitors: do they help preserve renal function?
Moro J; Almenar L; Martínez-Dolz L; Agüero J; Rueda J; Arnau MA; Izquierdo M; Cano O; Sánchez-Lázaro I; Salvador A
Transplant Proc; 2007 Sep; 39(7):2135-7. PubMed ID: 17889116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
